| mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.21 |
2e-07 |
| mRNA |
17-AAG |
CCLE |
pan-cancer |
AAC |
0.25 |
5e-07 |
| mRNA |
17-AAG |
GDSC1000 |
pan-cancer |
AAC |
0.14 |
8e-05 |
| mRNA |
Bleomycin |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
0.0003 |
| mRNA |
Crizotinib |
gCSI |
pan-cancer |
AAC |
0.22 |
0.001 |
| mRNA |
docetaxel:tanespimycin (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.11 |
0.002 |
| mRNA |
UNC0638 |
GDSC1000 |
pan-cancer |
AAC |
-0.1 |
0.002 |
| mRNA |
SNX-2112:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.11 |
0.002 |
| mRNA |
HG-5-88-01 |
GDSC1000 |
pan-cancer |
AAC |
-0.16 |
0.002 |
| mRNA |
thalidomide |
CTRPv2 |
pan-cancer |
AAC |
-0.18 |
0.002 |